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 FOREWORD 
This document is a Feasibility Study Report for minor enhancements to TG 414 Prenatal 
Developmental Toxicity Study to include endocrine disrupter-relevant endpoints.  The 
Feasibility report was prepared by Denmark (lead), and was part of Project 4.100 added to 
the Test Guidelines Programme work plan in April 2015.   
A call for TG 414 data was organised in 2015 and based on analyses of data identified, this 
report addresses the feasibility, scientific and technical concerns regarding inclusion of 
additional endpoints related to endocrine disruption measured in the rat fetus and dam.  
At the May and October 2017 EDTA meetings, Denmark presented initial findings on the 
sensitivity of anogenital distance measurements, peripheral testosterone levels and 
peripheral thyroid hormones (T4, T3, and TSH) in fetuses and thyroid hormones measured 
in dams. The documents discussed during the October 2017 meeting and synopsis of the 
discussion are available in the meeting summary record posted on the Clearspace site 
(https://community.oecd.org/community/edta).   
The draft report was revised following input from an expert group on Reproductive and 
Developmental Toxicity.  The expert group provided guidance through a series of 
teleconferences, the summary records of which can be found on the Clearspace site for 
Expertise in Test Guidelines (http://community.oecd.org/community.tgeg). 
Additionally, the draft Feasibility Report and revised TG 414 were circulated to the WNT 
and EDTA for two written commenting rounds in October and December 2017.  The 
revised final draft TG 414 is also available ENV/JM/TG (2018)18. 
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Terms of reference  
  
1. This Feasibility report for minor enhancements of TG 414 (Pre-natal 
Developmental Toxicity Study) with ED (endocrine disrupter)-relevant endpoints was 
prepared by the Division of Diet, Disease prevention and Toxicology, Research Group for 
Molecular and Reproductive Toxicology,  National Food Institute, Technical University of 
Denmark, which is leading the project in OECD. The report has given input for discussions 
in various groups in OECD. Subsequently, the report has been revised based on input after 
discussions in the OECD Expert Group on Reproductive and Developmental Toxicity 
Testing, at EDTA meetings and in WNT commenting rounds in OECD. 
Aim  
2. The aim of this project is to do a Feasibility study for minor enhancements of TG 
414 (Prenatal Developmental Toxicity Study) with ED-relevant endpoints. This report 
addresses feasibility, scientific and technical concerns regarding inclusion of these 
additional ED related endpoints in TG 414. The endpoints considered in this project 
included anogenital distance (AGD) in all fetuses, testosterone in male fetuses and 
guidance for genital malformations in all fetuses. Moreover, later in the process also thyroid 
measurement in fetuses and in the dams has been considered to be included. For these 
endpoints, the scientific and technical questions considered include: 
 Are standardized methods available? 
 Is the sensitivity sufficient with the number of litters per group?  
 Are the endpoints of relevance for humans? 
 Are there animal welfare concerns? 
 Is the enhancement possible without changes or with only minor changes in study design? 
Background and expected regulatory need/data requirement that will be met by the 
proposed outcome of the project 
 
3. A scientific approach will be used to give input to the existing TG 414 (Prenatal 
Developmental Toxicity Study) in relation to the feasibility of inclusion of sensitive 
endpoints in all fetuses and dams for detection of chemicals with endocrine disrupting 
properties.  
4. The specific purpose of this project is to consider the relevance and feasibility of 
enhancement of the OECD 414 (OECD, 2001). The TG 414 provides information on 
adverse effects on prenatal development and is used in various regulatory frameworks (such 
as REACH and several pesticide regulations) to generate information for risk assessment 
of chemicals.  
5. OECD TG 414 is included in Level 4 (OECD conceptual framework) as the TG 
involves repeated dosing of pregnant females and therefore potential exposure of the 
developing fetus. The assay includes some endpoints that may detect endocrine disruption 
(OECD, 2018a).  
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6. However, this update in relation to inclusion of more endpoints in TG 414 in dams 
or fetuses at the time of caesarean section could be a significant enhancement with regards 
to detection of effects of endocrine disrupting substances.  
7. After the inclusion on the work plan in OECD (as project number 4.100) the 
possibility to include thyroid hormones in the dams and/or fetuses has been mentioned in 
the OECD Expert Group on Reproductive and Developmental Toxicity Testing as well as 
at international meetings in 2017 (DG-Environment, 2017) and EDTA meetings in OECD 
in May and October 2017.  
8. The OECD Expert Group on Reproductive and Developmental Toxicity Testing 
(EG) from the update on TG 421/422 (Project 4.71 on OECD Workplan) has been 
convened as the scientific discussion is similar. Additional experts have been invited to the 
EG via the WNT NCs. These EG and the EDTA meetings in 2017 (May and October) have 
provided guidance on which endpoints to be considered and the feasibility (e.g. timing and 
logistics) based on a proposal from the lead.  
9. DK has undertaken the examination of available existing data. Data have been 
received from OECD countries and also peer reviewed scientific relevant papers have been 
included to make a proposal to the EG on whether or not it is relevant to include the ED 
related endpoints in a proposal for revision of OECD TG 414. 
10. It will also be considered whether certain slight adaptions of the test design of the 
test guideline may be warranted to include for consideration if other ED related endpoints 
are suggested by the EG for this project. However, the timing of the OECD TG 414 study 
cannot be changed as was the case in TGs 421/422 screening studies (which was terminated 
later due to assessment of Nipple retention).  
11. The results of this project may contribute to an improved sensitivity for 
identification of developmental toxicants in mammalian species at an early stage in the 
regulatory testing schemes for industrial chemicals (e.g. REACH) as information from TG 
414 is already required in such regulatory testing schemes.  
12. If these endpoints are implemented in TG 414 it will enhance the international 
harmonization of hazard assessment with regard to developmental toxicity effects.  
13. An important point is that the ability for detection of EDs should be enhanced 
without increasing the number of experimental animals used.  
14. TG 414 is designed to provide general information concerning the effects of 
prenatal exposure on the pregnant test animal and on the developing organism; this may 
include assessment of maternal effects as well as death, structural abnormalities, or altered 
growth in the fetus. The proposed update of TG 414 must not impair the ability to fulfil the 
purpose of TG 414.  
15. Assessment of AGD in both sexes is mandatory in TG 443 and TGs 421/422 and 
this report will elucidate whether this endpoint could also be included in TG 414 at the day 
of caesarean section.  
16. TG 414 was revised in 2001 but not with regard to inclusion of ED relevant 
endpoints. It seems relevant to include some ED relevant endpoints in TG 414 as the 
exposure periods cover some of the sensitive periods for sexual differentiation (prenatal 
period). The proposed endpoints are described below.   
17. The OECD TG 407 (Repeated dose 28- day oral toxicity study in rodents) has been 
updated in 2008. The assay has been validated for some endocrine endpoints but the 
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sensitivity of the assay is not sufficient to identify all EATS-mediated EDs. The validation 
of the assay (OECD, 2006) showed that it identified strong and moderate EDs acting 
through the ER and AR; and EDs weakly and strongly affecting thyroid function. It was 
relatively insensitive to weak EDs acting through the ER and AR. This assay also has some 
optional endpoints such as uterine and ovary weight, vaginal cytology (to provide a marker 
for physiological estrogenicity that would guide the histological interpretation of the ovary 
and estrogen-sensitive tissues), histopathologic changes in mammary gland histopathology 
(mandatory in females optional in males) as well as serum T3, T4, TSH as well as thyroid 
weight which can be examined if there is additional concern.   
18. The extended one-generation reproductive toxicity study (EOGRTS) (OECD, 
2012) includes more endpoints sensitive to endocrine disruption than OECD TG 416 
(OECD, 2001) and, as it also uses reduced animal numbers if conducted without F2. It is 
expected that it will often replace OECD TG 416 for mammalian reproductive toxicity 
testing (OECD GD 150, 2018a). Endpoints sensitive to endocrine disruption include 
anogenital distance at birth, areola/nipple retention, measurement of thyroid hormones and 
TSH levels. Effects on the developing nervous and immune systems are also assessed by 
the DNT and DIT cohorts. These systems may also be sensitive to endocrine influences. 
This test is also expected to have greater sensitivity than OECD TG 416 as it requires an 
increased number of pups to be examined. In summary, the new EOGRTS (OECD TG 443) 
is preferable for detecting endocrine disruption because it provides an evaluation of a 
number of endocrine endpoints in the juvenile and adult F1, which are not included in the 
2-generation study (OECD TG 416) adopted in 2001. 
19. In 2015 and 2016, the OECD 421 (Reproduction/Developmental Toxicity 
Screening Test) and OECD 422 (Combined Repeated Dose Toxicity Study with the 
Reproduction/ Developmental Toxicity Screening Test) guidelines were revised to include 
ED relevant endpoints (OECD, 2016a; OECD 2016b; OECD, 2015).  
20. In April 2015, OECD launched this feasibility study for the enhancement of OECD 
414 with selected parameters intended to increase the detection of EATS disrupting 
potential. In the autumn 2015 the lead and OECD secretariat requested data (control litter 
means + SD) from OECD member states to enhance TG 414 with endocrine disrupter 
relevant endpoints. All conclusions can be found in paragraph 100 of this report.  
Anogenital distance (AGD) 
Methodology  
21. New-born male rats have no scrotum, and the external genitalia are undeveloped, 
and only a genital tubercle is apparent for both sexes. The AGD is the distance from the 
anus to the insertion of this tubercle, the developing genital bud. The AGD is androgen 
dependent, and studies show that the AGD is normally about twice as long in male as in 
female rats. Similarly, in new-born humans the AGD measure was about two-fold greater 
in males than in females (Salazar-Martinez et al. 2004). At caesarean section, the distance 
between the proximal end of the anus and the genital tubercle of all fetuses must be 
measured. Anogenital distance is a non-invasive measure of in utero androgenicity. The 
distance will be measured from the base of the genital tubercle to the proximal end of the 
anal opening using a dissecting microscope with a micrometer eyepiece or another sensitive 
method. The fetal weight will be measured to derive anogenital index and the measurement 
need to be included as a covariate in the statistical analysis of AGD (OECD, 2008).  
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22. In TG 414 the AGD will be measured in both male and female fetuses in all litters 
at caesarean section one day prior to the expected day of delivery (OECD, 2018b). This 
report uses data from Wistar rats and Sprague Dawley rats which are relevant species 
commonly used in prenatal developmental toxicity testing.  
Data analysis, sensitivity and power 
23. Important parameters when evaluating the sensitivity and power of the data are i) 
the sample size of the data, ii) the standard deviation SD (σ) and iii) the target biological 
difference or ii) the coefficient of variation CoV (the ratio of the standard deviation to the 
mean of the sample) and iii) the target percent biological difference in the population mean 
µ. 
24. The standard deviation is an expression of how much the value disperses from the 
population mean (µ). Coefficient of variation is expressed as σ/µ and is often evaluated as 
a percentage and therefore expresses the standard deviation as the percentage of the 
population mean, µ. In the feasibility study of the screening studies (TGs 421/422), all 
statistical analysis was done on the basis of the coefficient of variation (OECD, 2015). 
25. In order to take into account the size of the rat when evaluating the AGD, the AGD 
was divided by the cubic root of the body weight, i.e. (AGD [mm])/∛(body weight [g]) 
resulted in the anogenital distance index (hereafter AGDI).  
26. The rat grows rapidly, as growth occurs in three dimensions so that body weight 
can be viewed as a cubic measure.  In contrast, AGD is a purely linear metric. Therefore 
the relationship between AGD and body weight should be more properly evaluated using 
the cube root of body weight as with AGDI or using the bodyweight as covariate in statistics 
(OECD, 2015; OECD, 2008).  
Data collection  
27. The evaluation of both AGD and plasma testosterone levels as endpoints is based 
on data from studies at DTU National food institute (only published), external (non-
published data from the expert group) and published studies primarily from Saillenfait et 
al. from The French National Research and Safety Institute for the Prevention of 
Occupational Accidents and Diseases (INRS) (Saillenfait, et al. 2009; Saillenfait et al, 
2011a and 2011b; Saillenfait, et al. 2013). The references for the data from DTU Food data 
is (Taxvig, et al. 2007; Taxvig, et al. 2008; Taxvig, et al. 2013; Hansen, et al. 2009; 
Kristensen, et al. 2011; Boberg et al. 2011).  
28. Unfortunately, the data sent from the expert group (unpublished) could not be 
included in the analysis. One dataset missed the information about litter affiliation and 
thereby group means based on litter means could not be obtained from these data. The other 
dataset did not give any details on the strain of rodent and could therefore not be compared 
with others.   
29. Furthermore, a literature search was conducted to increase the amount of data. The 
parameters for this search were based on the dosing period requirements in TG 414. 
“Normally, the test substance should be administered daily from implantation (e.g., day 5 
post mating) to the day prior to scheduled caesarean section […] Females should be killed 
one day prior to the expected day of delivery.” (OECD, 2001).The dosing period for the 
rats used in the DTU group (in house data) was GD 7 to 21 and GD 6-21 for the French 
group. GD 0 is understood as the day of mating and GD 21 is 3 weeks after (our Wistar or 
SD rats give birth at day 22 or 23).   
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30. In general, only few published papers satisfied the dosing period requirement in TG 
414, either because the administration of the compound was initiated later on (e.g. GD 12-
GD 17), or because the caesarean section was conducted before the expected day of 
delivery e.g. GD 19. Studies that did not sufficiently meet the dosing duration of OECD 
414 were excluded from the analysis (Parks et al., 2000; Ema et al., 2003; Fisher et al., 
2003; Hotchkiss et al., 2004; Thompson, et al., 2004; Liu et al., 2005; Saillenfait et al., 
2016). A reason for this deviation could be the scientific interest in the developmental 
stages in the embryotic phase or in the testosterone peak levels during the fetal 
development. 
31. Another important criterion was the presence of data in the papers that could 
actually be used for this analysis. Hence, data presentation in the form of graphs or bar 
charts was excluded because of inaccuracies when transforming these and therefore only 
data in the form of tables was included. 
Results 
32. To evaluate whether a specific endpoint is sensitive enough to be included in a test 
guideline, it is important to consider the control values. If large variations are present in 
these samples, the identification of any effect is hampered.  
 
Table 1. Overview of male AGD in control data GD 21, mean ± SD. Averages for all control group means, 
control group standard deviations (calculated using litter means) and coefficients of variation (of litter means) 
for the control groups are given. In relation to all calculated averages, the standard deviation (of litter means) 
is depicted. The total number of studies and the range of the number of litters for the control groups are also 
given. Importantly, the controls are also split with regards to the rat strain used. The data AGDI mean is a 
group mean (control) based of litter means in each study.  
 
 
 
33. An overview of all control data of AGD at GD 21 including the overall mean, 
standard deviation of litter means (i.e. between litter variation), and coefficient of variation 
of litter means are given in Table 1. 
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34. As seen in table 1 the combined Coefficient of Variation (of litter means) in male 
control fetuses is quite low (overall 4.03±1.67) even though most studies have much fewer 
litters than used in TG 414. However, it is also observed (Table 1, Figure 1) that Sprague-
Dawley rats in the French studies have a lower mean AGDI, standard deviation and 
coefficient of variation compared to Wistar rats. 
Table 2. Comparison of coefficients of variation for AGDI measured prenatally and postnatally. The given 
coefficients of variation are group means (control) based on litter means of all control group coefficients, 
mean ± SD. The total number of studies/experiments and the range of number of litters for the control groups 
are given. Only data on Wistar rats (from table 1) is included from DTU, DK to assure that data is from same 
laboratory.  
 
35. To evaluate whether the prenatal AGD measurement is sensitive enough it is also 
relevant to compare to postnatal data. The endpoint AGD is not feasible to include if the 
prenatal measurements has a much higher variation than postnatal measurement. The 
measurements must be consistent with standard deviations and coefficients of variation not 
greatly influenced by the gestation day compared to postnatal measurements. Table 2 and 
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Figure 1. Mean AGDI +SD at GD 21 male fetuses, i.e. the mean with 
corresponding SD for each control group for the studies included. Blue bars 
indicate Wistar rats (N=3-18 litters) and red bars indicate Sprague-Dawley rats (6-
25 litters). The DTU group in general uses Wistar rats (only one study with 
Sprague Dawley), whereas the French research group uses Sprague-Dawley rats 
only. 
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figure 2 outlines such a comparison between coefficients of variation for AGDI measured 
pre- and postnatally.  
36. As seen in table 2 the CoV for prenatal AGDI is 4.49 (9 studies) whereas in new 
born males it is 4.00 (23 studies). The given coefficients of variation are group means 
(control) based on litter means of all control group coefficients, mean ± SD. This indicates 
that the sensitivity/power for detecting effect on AGD is quite similar in GD 21 fetuses and 
new-born male pups.  For information the sample size in TG 414 studies is much larger 
than the studies included in this report (as number of litters in TG 414 is at least 20).  
37. As described above the analysis for tables 1 and 2 and figures 1 and 2 were 
calculated from group means based on litter means. In the expert group it was decided that 
a more superior approach and statistical model should be developed by US EPA 
statisticians to take into account the size of the studies (e.g. the number of litters included). 
They provided a SAS® code with a mixed model approach to facilitate the reanalysis. BIAC 
representatives in the expert group ran the reanalysis of the AGD data. The reanalysis 
included only a subset of the data included in this feasibility report (tables 1 and 2; figures 
1 and 2). These nine studies from the lead (DTU Food) were included for which there was 
individual animal data. The reanalysis resulted in an overall CoV (based on the total 
variance within study = between litters variance + within litter variance) of 7.0% and a 
between litter CoV (based on the between litters variance) of 4.18% was very close to the 
4.49% reported in table 1 and 2 above (original statistics).  
 
 
Figure 2. Mean coefficient of variation (group means based on litter means in each study) for prenatal 
studies: 4.49 ±1.69 % (9) and postnatal studies: 4.00 ±1.50 % (23 studies). For the prenatal studies 2 CoVs 
have the same value and therefore it looks like there are only 8 studies represented 
Human relevance 
38. In rats, both AGD and nipple retention have been shown to be highly predictive of 
or correlated to adverse effects of the male reproductive system including increased 
incidence of genital malformations (e.g. hypospadias) or dysgenesis, and or altered 
reproductive organ weight changes e.g. levator ani-bulbocavernosus (LABC) muscle 
complex (Bowman et al. 2003, Christiansen et al. 2008, van den Driesche et al. 2011, Welsh 
et al. 2008). In female rats, AGDs can in some cases also be affected by exposure to 
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endocrine disruptors. In most studies of anti-androgenic exposure, female AGDs have not 
been affected (Hass et al. 2007, Christiansen et al. 2009); however, androgen exposure has 
been shown to increase female AGD (Hotchkiss et al. 2007) and prochloraz exposure in 
utero has increased female AGD in several studies (Laier et al., 2006; Melching-Kollmuss 
et al., 2017). Exposure to oestrogenic agents like ethinyl estradiol (EE2) and genistein have 
been shown to increase or decrease female AGDs, depending on study design (Levy et al. 
1995, Casanova et al. 1999, Delclos et al. 2009, Mandrup et al. 2013). In two novel studies 
slight reductions in female pup AGD following butylparaben exposure (Boberg et al. 2016) 
and bisphenol A exposure (Christiansen et al., 2014) have been reported. Therefore AGD 
in both sexes is included in this TG.  
39. A shorter anogenital distance in humans has been shown to be associated with 
phthalate exposure (Bornehag et al. 2015). Recent studies reported that male infants and 
boys with adverse effects such as hypospadias or undescended testis also had reduced AGD 
(Hsieh et al. 2012; Hsieh et al. 2008; Jain and Singal 2013; Thankamony et al. 2013). 
Moreover, a shorter AGD in adult men has been related to decreased fertility (Eisenberg et 
al. 2011), impaired semen quality (Mendiola et al. 2011) and decreased serum testosterone 
levels (Eisenberg et al. 2012). Shortened AGD has also been suggested as a biomarker of 
testicular dysgenesis syndrome (Sharpe 2005).  
40. As AGD in both sexes is included as endpoint in OECD TG 443 and TG 421/422 
it can therefore be considered as an endpoint evaluated to be of human relevance. Moreover 
an updated ECHA guidance document stated that: “The findings in AGD, nipple retention 
and fetal T, suggest an anti-androgenic mode of action (androgen deficiency) and may be 
considered as relevant findings and predictors of potential adverse effect during human 
development.” (ECHA 2013). The OECD GD 43 and GD 151 states “A statistically 
significant change in AGD that cannot be explained by the size of the animal indicates 
effects of the exposure and should be considered in setting the NOAEL” (OECD 2008; 
OECD 2013). As the NOAEL can be used as the point of departure for setting safe exposure 
levels for humans this further supports that effects on AGD are of human relevance. 
Moreover, as observations of similar effects is seen in experimental animals and in humans 
support that AGD changes in experimental animals are relevant for humans. 
Animal welfare 
41. An important point to remember is that this TG can be enhanced with the ability 
for detection of EDs without increasing the number of experimental animals used.  
42. Assessment of AGD in fetus at caesarean section does not increase the number of 
experimental animals used, but requires marginally more handling of the fetuses. This 
assessment can be done very gently just before humane killing and is therefore not expected 
to lead to any animal welfare concerns.  
Inclusion of AGD in TG 414 
43. There are standardized OECD test methods for assessing AGD and AGD measured 
at birth (e.g. PD 1-4) have been included in several OECD TGs. Moreover, several studies 
(see table 1 and 2) have shown ability to measure AGD at caesarean section at GD 20 or 
21 (one day prior to the expected day of delivery). These studies have used a dissecting 
microscope with a micrometer eyepiece.  
44. The current report has shown that the power for assessment of AGD is almost equal 
in GD 21 fetuses versus in new-borns as the analysis showed similar CoV in these two time 
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points. Therefore this endpoint can be included in TG 414 at GD 21 without any 
modification of the overall test design. Several studies have also measured AGD with 
success in rats at GD 19 and 20. 
45. At the TC in EG statistical experts from the USEPA noted that it is important to 
ensure the CoV results analysed are statistically interpretable. The lead have therefore sent 
detailed data on 9 studies in order for USEPA to calculate the CoVs by using a mixed 
effects model to distinguish between variability between litters from variability between 
studies and to better address the sensitivity of the AGD endpoint. These results will be 
discussed in EG early 2018. 
46. AGD is an endpoint of high human relevance and there are no concerns for animal 
welfare related to the assessment of this endpoint (OECD, 2015).  
47. This all supports the assessment of AGD in all fetuses can be included in TG 414.  
Testosterone levels in male fetuses 
Method 
48. Changes in testosterone levels in sensitive prenatal time windows can cause 
permanent/long lasting reproductive changes in laboratory rats. Studies have shown that 
exposure during gestation to e.g. some phthalates, can show effects on testosterone 
synthesis, fetal testicular content or ex vivo testicular testosterone production in males 
fetuses leading to effects observed postnatally e.g. anogenital distance and reproductive 
organ weight changes (Borch et al. 2004, Saillenfait et al. 2013, Borch et al 2006).  
49. In general, only few other published papers satisfied the dosing period used in TG 
414, either because the administration of the compound was initiated later than in TG 414 
on (e.g. GD 12), or because the caesarean section was conducted before the expected day 
of delivery, most often at GD 19. Studies that did not sufficiently meet the dosing duration 
of OECD 414 were therefore excluded from the analysis (Parks et al., 2000; Fisher et al., 
2003; Hotchkiss et al., 2004; Lehmann et al., 2004; Thompson, Ross and Gaido, 2004; 
Saillenfait et al., 2016). A reason for this deviance could be the scientific interest in the 
developmental stages in the embryotic phase or in the testosterone peak levels during the 
fetal development.  
50. In relation to the feasibility of inclusion of testosterone hormone measurements the 
lead and expert group have discussed whether serum testosterone levels, testosterone 
synthesis (testicular) or ex vivo testosterone production in fetal testes would be the most 
suitable method.  
51. It was agreed that only measurement of testosterone hormones in the serum would 
be possible as other methods might impair the ability to fulfil the purpose of TG 414 that 
is designed to provide general information concerning the effects of prenatal exposure on 
the pregnant test animal and on the developing organism; this may include assessment of 
maternal effects as well as death, structural abnormalities, or altered growth in the fetus.  
52. Blood sampling in TG 414 (also other hormones) could be done by: 
o Cardiac puncture, can only be done for fetuses selected for skeletal assessment  
o Decapitation, will impact all fetal assessments 
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o The umbilical cord, will not impact fetal assessments but only gives a very small 
amount of blood (so blood of most fetuses/litter should be pooled)  
 This latter method is not relevant for testosterone as this should be only 
pooled by sex and the amount of blood might be too small.  
53. Fetal measurements of T4, T3 and TSH can be pooled from both sexes, however 
testosterone should not be pooled.  
Data analysis, sensitivity/power 
54. Weisz and Ward (1980) reported significantly higher serum testosterone levels in 
male rat fetuses compared to female fetuses with a peak at GD 18 and this finding was 
confirmed by Lichtensteiger and Schlumpf (1981, 1985). Due to this testosterone peak in 
male fetuses at GD18, this stage has been examined when the focus is on sexual 
dimorphism of sex steroid regulation. As already stated this TG 414 performs caesarean 
section the day before expected delivery and therefore it is not feasible to assess 
testosterone level in serum from other time-windows.  
55. As stated above, plasma testosterone levels have also been found to be affected by 
chemicals at subsequent fetal and neonatal stages, and have been related to developmental 
disturbances. This is why this project originally suggested determining plasma testosterone 
at around GD 21 in TG414.  
56. In many studies intratesticular testosterone levels rather than plasma levels were 
reported (Parks et al., 2000; Fisher et al., 2003; Hotchkiss et al., 2004; Lehmann et al., 
2004; Thompson, Ross and Gaido, 2004). This endpoint is however not feasible to include 
in TG 414 due to the purpose of the TG 414 (see paragraph 49).  
57. In Table 3, the overall mean and standard deviation for the individually measured 
mean plasma testosterone levels, the standard deviations and the coefficient of variation for 
each control experiment are presented. Furthermore, the number of control experiments 
included in the calculations and the range of the numbers of litters in these are stated. 
58. It is seen at table 3 that a large overall coefficient of variation of around 43% in 
controls is obtained indicating that the possibility for detecting effects is low. However, it 
is also seen that the number of litters included is relatively low compared the number of 
litters in TG 414, i.e. 3-9 litters per group compared to 20 litters per group in TG 414. 
Therefore the power for detecting effects is expected to be clearly higher in the TG 414 
than in those studies.  
59. Moreover, in two of the 7 studies (see figure 3), the coefficient of variation is 
actually around 20% in spite of the low number of litters per group. This indicates that the 
power for detecting effect with around 20 litters per group may be sufficient. 
60. Nevertheless, as also mentioned in this report several studies on EDs have shown 
significant effects on testosterone measurement in males fetuses. 
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Table 3. Overall mean ± SD for the mean level of plasma testosterone at GD 21, the standard deviation and 
the derived coefficient of variation for each study (7). Additionally, the number of studies/experiments and 
the range of number of litters in these are included.  
 
 
Figure 3. The mean plasma (based on litter means) testosterone level +SD in each control group for the 7 
studies included in this feasibility report. These studies included fewer animals pr. litter than in the TG 414.  
Human relevance 
61. Testosterone and dihydrotestosterone are two of the key hormone players in sex 
differentiation of a fetus and are both classified as sex steroid hormones (Melmed et al. 
2015). Therefore by measuring testosterone in TG 414 as an indication of endocrine 
disruption could indeed be relevant for human risk assessment. 
Animal welfare 
62. Blood samples for assessment of testosterone or other steroid hormones in fetus 
could be taken at caesarean section by termination of the study. This will lead to no concern 
for animal welfare, as the blood samples will be collected at the time of sacrifice.  
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Inclusion of testosterone in TG 414 
63. There are standardized test methods for assessing testosterone hormones in serum. 
The performed power analysis showed coefficient of variation of around 43% in controls 
indicating that the possibility for detecting effects is low. 
64. Nevertheless, several studies on EDs have shown effects on testosterone 
measurement in male fetuses. 
65. The feasibility study demonstrates large variations in sample measurements and the 
variation in controls for plasma testosterone is high. These data fail to demonstrate that this 
measurement is sensitive enough to be included in a test guideline. 
66. The inclusion of hormone measurement (testosterone and thyroid hormones) in 
fetuses was discussed in the EG after 1st commenting round. A representative from BIAC 
described recent research evaluating technical feasibility of collecting the additional 
endpoints (AGD, blood samples) from fetuses. To preserve the integrity of other endpoints 
in TG 414, blood samples were collected by cardiac puncture of fetuses selected for skeletal 
examination.  However, this added about 20-25 minutes per litter and fetuses were alive 
for up to 35 minutes between Caesarean section and necropsy, raising concerns on variation 
in processing time for animals within a litter which could lead to high variability in data. 
BIAC noted that in many cases, blood volumes collected from fetuses were limited and 
needed to be pooled for analyses. 
67. The EG recognised that there is large CoV in fetal testosterone in this report due to 
the gestational surge which occurs before GD 20, and thus this measurement has limited 
reliability. Overall, the group felt that there is not enough confidence in fetal testosterone 
to support including the testosterone measure in the revised TG. 
 
Thyroid hormones 
Method  
68. Thyroid hormones were included in the TGs 421/422 as blood samples from the 
day 13 pups and assessments of thyroid hormones (T4) in the adult males was required 
(OECD, 2015). In contrast, further assessment of T4 in blood samples from the dams and 
day 4 pups is to be done if relevant. Moreover the TGs also include an option for other 
hormones. 
69. Due to the circadian rhythm of thyroid hormones, sample collection should occur 
at approximately the same time of day and be randomized across dosage groups, preferably 
in the morning hours at which time basal values should be present (Döhler et al., 1979).   
70. Blood samples for evaluation of triiodothyronine (T3), thyroxine (T4), and TSH 
should be collected immediately following sacrifice.  
71. Hormonal analyses should be conducted on dams only in this TG 414.  
72. Prior to sacrifice, every effort should be made to avoid inducing stress that could 
affect hormone concentrations (Döhler et al., 1979).  
73. When the inclusion of thyroid hormones in the dams was discussed in the EG it 
was suggested that the revised guideline specify that blood should be collected from dams 
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within a short timeframe (i.e. two hours) on the morning of the day of necropsy to reduce 
variability in thyroid hormone levels. Fasting is not necessary for the blood sampling.  
74. It was also noted that only non-pregnant dams should be excluded from analyses, 
and though all blood samples should be collected. 
Data analysis, sensitivity/power 
75. The number of animals included in TG 414 is similar to the number of animals in 
TG 443, where assessment of thyroid hormones is included. Thus, specific data analysis of 
power related to number of animals is not needed here.  
76. Moreover, the feasibility study from TGs 421/422 (OECD, 2015) included 
intensive power simulations for TH measurements with even fewer animals.  
77. However, blood samples will be taken in dams in TG 414 compared to non-
pregnant adult animals in TG 443 and TG 421/422 (males). This may affect the sensitivity.   
Human relevance 
78. Thyroid hormones (TH) are needed for proper nerve cell differentiation and 
proliferation, and normal status of these hormones during early development is therefore 
crucial. In humans even moderate and transient reductions in maternal T4 levels during 
pregnancy, may adversely affect the child’s neurological development (OECD, 2015; DG-
environment, 2017).  
79. This indicates that by measuring thyroid hormones (T4, T3 and TSH) in dams in 
TG 414 as an indication of thyroid disruption is relevant for human risk assessment as also 
described in the feasibility study for TGs 421/422 (OECD, 2015). 
Animal welfare 
80. Blood samples for assessment of thyroid hormones could be taken at caesarean 
section by termination of the study. This leads to no concern for animal welfare, as the 
blood samples will be collected at the time of sacrifice.  
81. Blood samples will be collected from all dams at termination for mandatory 
assessment of thyroid hormones T4 and T3 or TSH (within a short timeframe (i.e. two 
hours) on the morning of the day of necropsy). 
Inclusion of thyroid hormones in TG 414 
82. There are standardized OECD test methods for assessing thyroid hormones. The 
performed power analysis in TGs 421/422 made in the feasibility study supported that 
assessment of thyroid hormones could also be included in these TGs. 
83. Thyroid hormone measurements (T3, T4 and TSH) will be included as mandatory 
endpoints in the updated TG 408 (90 day study).  
84. Therefore the assessment of thyroid hormones in TG 414 dams is sufficiently 
sensitive to provide relevant data.  
85. Due to the adverse effects seen in humans after developmental hypothryoxinemia, 
this endpoint is of high human relevance and there are no concerns for animal welfare 
related to the assessment of this endpoint as long as blood sampling is done in animals that 
are being sacrificed anyway. 
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86. The revised TG 414 will include mandatory measures of T4, T3, and TSH from the 
dams.  As agreed by EG the revised guideline will specify that blood should be collected 
from dams within a short timeframe (i.e. two hours) on the morning of the day of necropsy 
to reduce variability in thyroid hormone levels. Fasting is not necessary for the blood 
sampling.  
87. The EG discussed proposed inclusion of optional T4, T3, and TSH measures in 
male and female fetal blood in the revised TG 414 after 1st commenting round (see 
paragraphs 66-67). The EG discussed possible criteria to trigger the optional endpoints, but 
no considerations were agreed upon by the group.  Several experts noted that if other 
indications of potential thyroid impairment were observed (e.g. decrease T4 among dams 
in TG 414), it may be more helpful to request data from guidelines that include more 
specific information and adverse responses (e.g. neurodevelopmental endpoints). There 
was no clear support for including optional blood samples in TG 414 revision without 
considerations for when these should be included. Moreover the fetal blood samples would 
add extra processing time for animals within a litter which could lead to high variability in 
data (see paragraphs 66-67). It was then decided by the EG to not include any serum 
hormone measurements from fetuses in TG 414.  
Abnormalities of external genital organs 
Method 
88. In TG 414 the reproductive tract is examined for signs of altered development. The 
SPSF in this project have described guidance on evaluation of abnormalities of external 
genitalia in fetuses such as hypospadias (Hsieh et al. 2007). However, Hsieh et al. (2007) 
used histopathological examination of the genital tubercle to detect hypospadias.  
89. In the TG 414 it is mentioned (paragraph 32) Particular attention should be paid 
to the reproductive tract which should be examined for signs of altered development. This 
project has also included the following text: External fetal sex (as determined by gross 
examination) should be compared with internal (gonadal) sex in all fetuses (examined for 
both skeletal and soft tissue malformations).  In addition, indication of incomplete 
testicular descent/cryptorchidism should be noted in male fetuses. 
Data analysis, sensitivity/power 
90. The feasibility study for TG 421/422 (OECD, 2015) included a calculation of the 
effect size needed for finding significant effect for abnormalities/malformations early 
postnatally.   
91. This limited sensitivity for detecting significant effects on rare adverse outcomes is 
generally recognized for malformations or dysgenesis. Thus, the occurrence of a few 
similar rare genital malformations may generally be considered toxicologically relevant 
although the finding is not statistically significant (OECD, 2015). The new text on 
cryptorchidism in TG 414 is therefore supported.   
Human relevance 
92. Exposure during critical developmental phases such as in utero and in the early 
postnatal period may lead to adverse effects on reproductive development. The fact that 
many of the basic mechanisms underlying this developmental process are similar in many 
known species of mammals indicates that chemicals that have adverse effects on 
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reproductive development in rodents should be considered as potential human reproductive 
toxicants as well (Gray 1992). 
Animal welfare 
93. Assessment of abnormalities of external genital organs requires slightly more 
handling of fetuses. This assessment can be done very gently and is therefore not expected 
to lead to any animal welfare concerns. However, as the assessment of abnormalities of 
external genital organs is done after termination of the fetuses in TG 414, there will 
obviously be no concern for animal welfare. 
Inclusion abnormalities of external genital organs in TG 414 
94. Assessment of abnormalities is already included in TG 414 (paragraph 32). The 
proposed text to be added in the revised TG 414 in relation to external fetal sex (as 
determined by gross examination) and internal (gonadal) sex in all fetuses and indication 
of incomplete testicular descent/cryptorchidism is now added in new paragraph 30 in TG 
414. This inclusion is agreed by EG and is already common practice according to BIAC.  
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Overall discussion and conclusions 
 
95. The aim of this project was to do a feasibility study for minor enhancements of TG 
414 with ED-relevant endpoints. The endpoints considered for inclusion in the SPSF were 
AGD, testosterone levels in fetuses, thyroid hormones in the dams and fetuses and more 
guidance on abnormalities of external genital organs.  
96. The EG have decided not to include any serum hormone measurements in fetuses 
because of too large CoVs and moreover these measurements would be time consuming 
and thereby impair the ability to fulfil the purpose of TG 414. 
97. For all included endpoints, OECD test methods are available for assessing these 
however this is the first TG to include thyroid hormones in pregnant dams. Calculation of 
CoVs for AGD has shown that it is a sufficiently sensitive endpoint to get relevant data 
with the number of litters per group in TG 414. All endpoints are of relevance for humans 
as described in this report. Inclusion of the additional endpoints in TG 414 does not trigger 
any animal welfare concerns.  
98. The Test Guideline has been updated with specific text proposals. No changes in 
study design and only few text changes are necessary to include the assessment of 
anogenital distance (AGD) in all fetuses, thyroid hormone measurements (in the dams only) 
and text on a text on external and internal fetal sex (see paragraph 32; OECD, 2018b).   
99. In conclusion, it is feasible to make the proposed minor enhancements of TG 414 
with ED-relevant endpoints: anogenital distance (AGD), thyroid hormones (in dams) and 
text on external and internal fetal sex and indication of incomplete testicular 
descent/cryptorchidism.  
100. Following discussions with EG and two WNT written commenting rounds the final 
proposed revision for the updated TG 414 (OECD, 2018b) includes:  
1. Mandatory AGD measurement in all fetuses (paragraph 30) 
2. Mandatory T4, T3 and TSH mandatory measurement in dams; other hormone 
measurements if relevant (paragraph 35) 
3. Observation of external fetal sex (as determined by gross examination) and internal 
(gonadal) sex in all fetuses (paragraph 32) 
4. Indication of incomplete testicular descent/cryptorchidism in male fetuses (paragraph 
32).  
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